Patients with chronic kidney disease (CKD) exhibit tremendously elevated risk for
cardiovascular disease, particularly ischemic heart disease, due to premature vascular and …

Osteoporosis is a systemic skeletal disease characterized by low bone mass and
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility …

Osteoporosis is an age-related disorder characterized by progressive bone loss and
impaired bone regeneration following surgery. The key to the treatment of osteoporosis is …

Osteoporosis is a systemic bone disease characterized by low bone mass,
microarchitectural deterioration, increased bone fragility, and fracture susceptibility. It …

Chronic kidney disease (CKD) is a highly prevalent disease that has become a public health
problem. Progression of CKD is associated with serious complications, including the …

There is limited evidence on the use of romosozumab (ROMO) in the treatment of
osteoporosis in patients on hemodialysis (HD); thus, we aimed to investigate this topic. This …

Renal osteodystrophy (ROD) is a common complication of end-stage kidney disease that
often starts early with loss of kidney function, and it is considered an integral part in …

We evaluated the pharmacokinetics, pharmacodynamics, and safety of a single
subcutaneous dose of romosozumab 210 mg, a monoclonal antibody against sclerostin, in …

Osteocytes are the most abundant type of bone cell and play crucial roles in bone health.
Osteocytes sense mechanical stress and orchestrate osteoblasts and osteoclasts to …

Purpose Osteoporosis poses a challenge to public health, causing fragility fractures,
especially in postmenopausal women. Abaloparatide (ABL) is an effective anabolic agent to …